The estimated Net Worth of Rajinder Singh is at least $2.27 million dollars as of 15 April 2019. Rajinder Singh owns over 33,000 units of ChemoCentryx Inc stock worth over $2,267,492 and over the last 9 years Rajinder sold CCXI stock worth over $0.
Rajinder has made over 3 trades of the ChemoCentryx Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Rajinder exercised 33,000 units of CCXI stock worth $69,300 on 15 April 2019.
The largest trade Rajinder's ever made was exercising 33,000 units of ChemoCentryx Inc stock on 15 April 2019 worth over $69,300. On average, Rajinder trades about 8,286 units every 67 days since 2016. As of 15 April 2019 Rajinder still owns at least 43,614 units of ChemoCentryx Inc stock.
You can see the complete history of Rajinder Singh stock trades at the bottom of the page.
Rajinder's mailing address filed with the SEC is C/O CHEMOCENTRYX, INC., 850 MAUDE AVENUE, MOUNTAIN VIEW, CA, 94043.
Over the last 13 years, insiders at ChemoCentryx Inc have traded over $355,980,520 worth of ChemoCentryx Inc stock and bought 3,166,975 units worth $19,475,662 . The most active insiders traders include Plc Gsk, Rishi Gupta et (International) Ltd Vifor P.... On average, ChemoCentryx Inc executives and independent directors trade stock every 12 days with the average trade being worth of $4,175,785. The most recent stock trade was executed by Susan M Kanaya on 16 August 2022, trading 19,898 units of CCXI stock currently worth $216,092.
ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx's lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration. Avacopan is also in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.
ChemoCentryx Inc executives and other stock owners filed with the SEC include: